TELA Bio, Inc. (NASDAQ:TELA) Stock Has Consensus Price Target of $2.14

TELA Bio, Inc. (NASDAQ:TELA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $2.14.

TELA has been the subject of several recent research reports. UBS Group set a $2.00 price objective on TELA Bio in a report on Friday, September 25th. Craig Hallum began coverage on TELA Bio in a research report on Friday, September 25th. They issued a “buy” rating and a $2.00 target price on the stock. Wall Street Zen raised TELA Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Finally, Weiss Ratings raised shares of TELA Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th.

Get Our Latest Analysis on TELA Bio

TELA Bio Stock Down 5.3%

Shares of TELA Bio stock opened at $0.69 on Friday. The stock has a market capitalization of $25.33 million, a P/E ratio of -0.93 and a beta of 1.46. The stock has a 50 day moving average price of $1.02 and a two-hundred day moving average price of $0.84. TELA Bio has a 12-month low of $0.50 and a 12-month high of $1.50.

TELA Bio (NASDAQ:TELA – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $18.96 million for the quarter, compared to the consensus estimate of $20.00 million. TELA Bio had a negative net margin of 53.57% and a negative return on equity of 1,320.81%.

Insider Buying and Selling at TELA Bio

In other TELA Bio news, Director Joseph Capper bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were acquired at an average cost of $1.06 per share, with a total value of $53,000.00. Following the acquisition, the director owned 154,827 shares of the company’s stock, valued at $164,116.62. The trade was a 47.70% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have bought 100,000 shares of company stock worth $109,000. 1.10% of the stock is owned by insiders.

Hedge Funds Weigh In On TELA Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rollins Financial Advisors LLC bought a new position in shares of TELA Bio in the 3rd quarter valued at $33,000. StoneX Group Inc. bought a new stake in shares of TELA Bio during the 3rd quarter worth $34,000. UP Strategic Wealth Investment Advisors LLC bought a new stake in shares of TELA Bio during the 2nd quarter worth $91,000. Wavvest Wealth LLC bought a new stake in shares of TELA Bio during the 3rd quarter worth $96,000. Finally, Marshall Wace LLP acquired a new stake in TELA Bio in the third quarter valued at about $141,000. 94.35% of the stock is owned by institutional investors and hedge funds.

TELA Bio Company Profile

(Get Free Report)

TELA Bio is a medical technology company that develops and markets products for soft-tissue reconstruction. Its portfolio includes OviTex Reinforced Tissue Matrices, which combine biologic materials derived from ovine (sheep) tissue with polymer reinforcement. The products are designed to support tissue repair and are used in procedures including hernia and abdominal wall reconstruction. The company also offers products for plastic and reconstructive surgery, including OviTex PRS, and other solutions for soft-tissue repair.

Further Reading

Analyst Recommendations for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.